X

Trial Profile

BHP Early Infant Treatment Study: a Clinical Treatment Trial of HIV+ Infants in Botswana

Status: Active, no longer recruiting

Phase of Trial: Phase II/III

Latest Information Update: 23 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lamivudine (Primary) ; Lopinavir/ritonavir (Primary) ; Nevirapine (Primary) ; Zidovudine (Primary)
Indications HIV-1 infections
Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
Acronyms EIT Study

Most Recent Events

17 Oct 2022 Planned End Date changed from 1 May 2022 to 30 Jun 2029.
03 Aug 2021 New trial record
28 Jul 2021 Results of an analysis from EIT cohort Botswana in infants (n=27) and maternal plasma genotyping (n=22) assessing occurrence of HIV drug resistance mutation in both intact and defective HIV-1 cell-associated DNA among early-treated infants published in the AIDS

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com